Akums Launches Novel Formulations For Patients With Gastrointestinal Disorders

New Delhi: Akums Drugs & Pharmaceuticals Ltd on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

“Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement.

Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed.

“We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement.

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Related Posts

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) on Wednesday announced that manufacturers may increase prices of scheduled formulations included in the National List of Essential Medicines (NLEM) by 0.64…

Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

New Delhi: The Union Government has clarified that the regulation, licensing, and oversight of hair transplant and cosmetic surgery clinics remain primarily the responsibility of State Governments and Union Territories,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

24-year-old woman dies during surgery; Five UP doctors booked for negligence

24-year-old woman dies during surgery; Five UP doctors booked for negligence

Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025